Nanologica (NICA) Q2 2026 earnings summary

Executive summary

• Net sales for Q2 2026 reached SEK 24.3 million, a significant increase from SEK 2.3 million year-over-year, mainly due to the consolidation of Syntagon.

• Operating profit for Q2 was SEK -18.1 million (Q2 2025: SEK -11.3 million); for H1, operating profit was SEK 49.0 million, positively impacted by SEK 75.7 million in negative goodwill from the Syntagon acquisition.

• Syntagon contributed SEK 22.8 million to Q2 net sales, while Nanologica contributed SEK 2.5 million.

• The integration of Syntagon and expansion of the sales organization were key operational focuses.

Financial highlights

• Net sales for H1 2026 were SEK 45.8 million (H1 2025: SEK 13.1 million).

• Profit before tax for Q2 was SEK -18.7 million (Q2 2025: SEK -12.8 million); for H1, SEK 47.1 million (H1 2025: SEK -23.0 million).

• Earnings per share for Q2 were SEK -0.06 (Q2 2025: SEK -0.15); for H1, SEK 0.66 (H1 2025: SEK -0.28).

• Cash and cash equivalents at June 30, 2026, were SEK 19.1 million (June 30, 2025: SEK 26.4 million).

• Equity at period end was SEK 156.4 million (June 30, 2025: SEK 51.1 million).

Outlook and guidance

• Priorities for H2 2026 include increasing Syntagon’s sales and profitability and converting Nanologica’s customer pipeline into commercial orders.

• Large-scale silica production is now stable, supporting future commercialization and sales growth.

• The company expects continued sales growth in chromatography products and contract manufacturing.